The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann–Pick disease

SummaryPatients with types A and B Niemann–Pick disease (NPD) have an inherited deficiency of acid sphingomyelinase (ASM) activity. The clinical spectrum of this disorder ranges from the infantile, neurological form that results in death by 3 years of age (type A NPD) to the non-neurological form (type B NPD) that is compatible with survival into adulthood. Intermediate cases also have been reported, and the disease is best thought of as a single entity with a spectrum of phenotypes. ASM deficiency is panethnic, but appears to be more frequent in individuals of Middle Eastern and North African descent. Current estimates of the disease incidence range from ~0.5 to 1 per 100 000 births. However, these approximations likely under estimate the true frequency of the disorder since they are based solely on cases referred to biochemical testing laboratories for enzymatic confirmation. The gene encoding ASM (SMPD1) has been studied extensively; it resides within an imprinted region on chromosome 11, and is preferentially expressed from the maternal chromosome. Over 100 SMPD1 mutations causing ASM-deficient NPD have been described, and some useful genotype–phenotype correlations have been made. Based on these findings, DNA-based carrier screening has been implemented in the Ashkenazi Jewish community. ASM ‘knockout’ mouse models also have been constructed and used to investigate disease pathogenesis and treatment. Based on these studies in the mouse model, an enzyme replacement therapy clinical trial has recently begun in adult patients with non-neurological ASM-deficient NPD.

[1]  P. Quinn,et al.  Membrane lipid homeostasis. , 2004, Sub-cellular biochemistry.

[2]  R. Desnick,et al.  Infusion of recombinant human acid sphingomyelinase into Niemann‐Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  John Calvin Reed,et al.  Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine -1-phosphate therapy , 2000, Nature Medicine.

[4]  R. Desnick,et al.  Niemann-Pick disease: a frequent missense mutation in the acid sphingomyelinase gene of Ashkenazi Jewish type A and B patients. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Huber,et al.  Alterations in blood-brain barrier ICAM-1 expression and brain microglial activation after lambda-carrageenan-induced inflammatory pain. , 2006, American journal of physiology. Heart and circulatory physiology.

[6]  J. Genest,et al.  Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol , 2003, Human Genetics.

[7]  C. Devlin,et al.  Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function. , 2000, Human molecular genetics.

[8]  E. Schuchman,et al.  Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. , 1997, Genetic testing.

[9]  R. Desnick,et al.  Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase (SMPD1). , 1992, Genomics.

[10]  R. Desnick,et al.  Niemann-Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. , 1991, The Journal of clinical investigation.

[11]  A. Crocker.  THE CEREBRAL DEFECT IN TAY‐SACHS DISEASE AND NIEMANN‐PICK DISEASE * , 1961, Journal of neurochemistry.

[12]  R. Desnick,et al.  Type A Niemann‐Pick disease: A frameshift mutation in the acid sphingomyelinase gene (fsP330) occurs in Ashkenazi Jewish patients , 1993, Human mutation.

[13]  K. Sandhoff,et al.  Phosphatidylinositol-3,5-Bisphosphate Is a Potent and Selective Inhibitor of Acid Sphingomyelinase , 2003, Biological chemistry.

[14]  J. Opitz,et al.  Replacement therapy for inherited enzyme deficiency: liver orthotopic transplantation in Niemann-Pick disease type A. , 1977, American journal of medical genetics.

[15]  R. A. Wevers,et al.  The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.

[16]  Z. Fuks,et al.  Radiation and ceramide-induced apoptosis , 2003, Oncogene.

[17]  E. Schuchman,et al.  A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death Published, JLR Papers in Press, September 8, 2005. DOI 10.1194/jlr.M500136-JLR200 , 2005, Journal of Lipid Research.

[18]  W. Stoffel,et al.  Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease) , 1995, Cell.

[19]  R. Desnick,et al.  Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. , 1991, The Journal of biological chemistry.

[20]  R. Desnick,et al.  Lipid abnormalities in children with types A and B Niemann Pick disease. , 2004, The Journal of pediatrics.

[21]  R. Kolesnick,et al.  Raft ceramide in molecular medicine , 2003, Oncogene.

[22]  Z. Fuks,et al.  Niemann–Pick Disease versus acid sphingomyelinase deficiency , 2001, Cell Death and Differentiation.

[23]  R. Desnick,et al.  Identification and expression of a common missense mutation (L302P) in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-Pick disease patients , 1992 .

[24]  V. Friedrich,et al.  Biochemical, pathological, and clinical response to transplantation of normal bone marrow cells into acid sphingomyelinase-deficient mice. , 1998, Transplantation.

[25]  N. Stolf,et al.  Niemann-Pick disease in adult: report of a case surgically treated. , 1983, Revista do Hospital das Clínicas.

[26]  S. M. Van Patten,et al.  Activation of Human Acid Sphingomyelinase through Modification or Deletion of C-terminal Cysteine* , 2003, Journal of Biological Chemistry.

[27]  R. Desnick,et al.  Niemann–Pick disease: Sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant , 2003, Journal of Inherited Metabolic Disease.

[28]  T. Taksir,et al.  Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Lang,et al.  Functional characterization of the postulated intramolecular sphingolipid activator protein domain of human acid sphingomyelinase , 2004, Biological chemistry.

[30]  T. Cox.  Substrate reduction therapy for lysosomal storage diseases , 2005, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[31]  S. Brodie,et al.  Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. , 2006, The Journal of pediatrics.

[32]  Jeffrey R Marks,et al.  Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[33]  J. Zeman,et al.  Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study , 2005, Journal of Inherited Metabolic Disease.

[34]  K. Williams,et al.  Zn2+-stimulated Sphingomyelinase Is Secreted by Many Cell Types and Is a Product of the Acid Sphingomyelinase Gene* , 1996, The Journal of Biological Chemistry.

[35]  M. Bakovic,et al.  Lipid rafts in health and disease , 2007, Biology of the cell.

[36]  R. Kolesnick,et al.  Acid sphingomyelinase-derived ceramide signaling in apoptosis. , 2002, Sub-cellular biochemistry.

[37]  X. Lv,et al.  D609 blocks cell survival and induces apoptosis in neural stem cells. , 2006, Bioorganic & medicinal chemistry letters.

[38]  R. Desnick,et al.  Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. , 2006, Radiology.

[39]  V. Friedrich,et al.  Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann–Pick disease , 2000, Gene Therapy.

[40]  A. Nicholson,et al.  Successful treatment of endogenous lipoid pneumonia due to Niemann-Pick Type B disease with whole-lung lavage. , 2002, American journal of respiratory and critical care medicine.

[41]  R. Kolesnick,et al.  Regulation of ceramide production and apoptosis. , 1998, Annual review of physiology.

[42]  Jae-Ho Park,et al.  Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease. , 2006, American journal of human genetics.

[43]  Y. Hannun,et al.  The complex life of simple sphingolipids , 2004, EMBO reports.

[44]  Q. Wan,et al.  A novel polymorphism in the human acid sphingomyelinase gene due to size variation of the signal peptide region. , 1995, Biochimica et biophysica acta.

[45]  J. Bertranpetit,et al.  Highly variable neural involvement in sphingomyelinase-deficient Niemann-Pick disease caused by an ancestral Gypsy mutation. , 2006, Brain : a journal of neurology.

[46]  V. Muzykantov,et al.  A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1 , 2003, Journal of Cell Science.

[47]  K. Higaki,et al.  [Niemann-Pick disease [type A and B] (acid sphingomyelinase deficiencies)]. , 1998, Ryoikibetsu shokogun shirizu.

[48]  B. Bembi,et al.  Treatment of Patients wIth Niemann-Pick Type Is Using Repeated Amniotic Epithelial Cells Implantation: Correction of Aggregation and Coagulation Abnormalities , 1997, Clinical pediatrics.

[49]  E. Schuchman,et al.  Mannose 6-Phosphate Receptor-mediated Uptake Is Defective in Acid Sphingomyelinase-deficient Macrophages , 2004, Journal of Biological Chemistry.

[50]  K. Sandhoff,et al.  Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa , 1993, Human Genetics.

[51]  R. Brady,et al.  The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[52]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[53]  Jian‐Qiang Fan.  A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. , 2003, Trends in pharmacological sciences.

[54]  Seamus J. Martin,et al.  Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis , 1996, Cell.

[55]  E. P. Kennedy,et al.  Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. , 1967, Journal of lipid research.

[56]  K. Suzuki,et al.  Infantile Niemann-Pick disease. A chemical study with isolation and characterization of membranous cytoplasmic bodies and myelin. , 1969, American journal of diseases of children.

[57]  O. Amaral,et al.  Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.

[58]  R. Desnick,et al.  The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. , 2002, American journal of human genetics.

[59]  V. Muzykantov,et al.  Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  E. Gulbins,et al.  Ceramide, membrane rafts and infections , 2004, Journal of Molecular Medicine.

[61]  K. Manova,et al.  Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. , 2002, Genomics.

[62]  E. Schuchman,et al.  Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of acid sphingomyelinase knockout mice. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  B. Bembi,et al.  Acid sphingomyelinase: Identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in‐frame start codon , 2004, Human mutation.

[64]  D. Adler,et al.  The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. , 1999, Genomics.

[65]  B. Scaggiante,et al.  Successful therapy of Niemann-Pick disease by implantation of human amniotic membrane. , 1987, Transplantation.

[66]  E. Schuchman,et al.  Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. , 1999, Biochimica et biophysica acta.

[67]  J. Ellingboe,et al.  Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[68]  R. Gordon,et al.  Analysis of the Lung Pathology and Alveolar Macrophage Function in the Acid Sphingomyelinase–Deficient Mouse Model of Niemann-Pick Disease , 2001, Laboratory Investigation.

[69]  D. Adler,et al.  Regional assignment of the human acid sphingomyelinase gene (SMPD1) by PCR analysis of somatic cell hybrids and in situ hybridization to 11p15.1----p15.4. , 1991, Genomics.

[70]  R. Desnick,et al.  An MspI polymorphism in the human acid sphingomyelinase gene (SMPD1). , 1991, Nucleic acids research.

[71]  U. Alon,et al.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. , 2001, Cancer research.

[72]  R. Desnick,et al.  AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  D. Perl,et al.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.